<!DOCTYPE html>
<html lang="en">
<head>
    <title>REDARK | MAKE DATA FOR RARE DISEASES</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="description" content="HTML5 website template">
  <meta name="keywords" content="global, template, html, sass, jquery">
  <meta name="author" content="Bucky Maler">
  <link rel="icon" href="assets/img/logo.png" type="image/x-icon">
  <link rel="stylesheet" href="assets/css/main.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.1/css/all.min.css">
    <style>
        /* Full-page animated background */
        body {
            margin: 0;
            padding: 0;
            height: 100vh;
            overflow: hidden;
            display: flex;
            justify-content: center;
            align-items: center;
            background: linear-gradient(45deg, #ff0000, red, darkred, #ff0000);
            animation: gradientAnimation 10s ease infinite;
            font-family: 'Vazir', sans-serif;
            overflow: scroll; 
        }

        @keyframes gradientAnimation {
            0% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
            100% { background-position: 0% 50%; }
        }

        .black-box {
            background: rgba(0, 0, 0, 0.9);
            border-radius: 15px;
            padding: 30px;
            box-shadow: 0 8px 30px rgba(0, 0, 0, 0.5);
            width: 90%;
            margin-top: 300px;
            max-width: 1200px;
        }

        .table-title {
            color: white;
            font-size: 20px;
            text-align: right;
            margin-bottom: 25px;
            border-bottom: 1px solid rgba(255,255,255,0.2);
            padding-bottom: 10px;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            color: white;
        }

        th, td {
            padding: 14px;
            text-align: center;
            border: 1px solid #444;
        }

        th {
            background: rgba(255, 255, 255, 0.05);
            font-weight: 600;
        }

        tr:hover td {
            background: rgba(255, 255, 255, 0.1);
        }

        th:first-child,
        td:first-child {
            text-align: right;
            width: 35%;
        }

        .feature-column {
            color: #ff4444;
            font-weight: 500;
        }
        .price-row {
            background: rgba(255, 255, 255, 0.03);
        }

        .price-row td {
            border: none;
            padding: 20px;
            font-size: 14px;
        }        .hint {
            font-size: 12px;
            color: #aaa;
            margin-top: 20px;
            text-align: left;
        }
        p{
            color:white;
        }
    </style>
</head>
<body>
    <div class="black-box">
      <p>Technical Report: DMD SynthData Generator Pro MAX v4.0
Silent & Efficient Synthetic Medical Data Generation System

Core System Specifications
1. Epidemiology-Driven Architecture
Genetic Mutation Prevalence:

7 mutation classes modeled on real-world epidemiological studies, including:

Exon45-50 Deletion (32% prevalence)

Exon2-10 Duplication (17%)

Nonsense Mutations (11%)

Other variants with weighted probabilities

Age of Onset: Skewed normal distribution (a=0.85, mean=4.2 years, SD=1.1 years) with clinical cutoff limits (1.5–7.8 years).

Longitudinal Visit Scheduling:

Dynamic intervals based on disease progression stages:

Early Stage: 180-day intervals (≤8 visits)

Intermediate Stage: 90-day intervals (9–14 visits)

Advanced Stage: 45-day intervals (≥15 visits)

2. Biomarker Progression Models
Forced Vital Capacity (FVC):

Mutation-specific decline rates (e.g., 0.18% per visit for Nonsense variants)

Steroid therapy modifiers:

Deflazacort: +4.2% FVC preservation

Prednisone: +3.5% FVC preservation

Left Ventricular Ejection Fraction (LVEF):

Linear decline at 0.8% per visit across all genotypes

3. Synthetic Patient Generation
Demographic Realism:

Birthdates randomized (1988–2021) with month-level granularity

Steroid treatment distribution: 60% Deflazacort, 35% Prednisone, 5% untreated

Cryptographic Anonymization:

Patient IDs generated via BLAKE2b hashing (16-byte digest) to prevent re-identification

Data Generation Workflow
Patient Synthesis

Genetic profile assignment via weighted probability sampling

Steroid therapy randomization

Age-of-onset calculation using skewed normal distribution

Longitudinal Visit Simulation

Stage-dependent visit scheduling

Biomarker decay modeling with treatment effects

Temporal alignment of FVC/LVEF trajectories

Output Optimization

Columnar storage in Apache Parquet format

Zstandard compression (Level 3) for 65% storage reduction

Categorical encoding for disease stages

Clinical Research Applications
1. Therapeutic Outcome Simulation
Compare steroid efficacy across genetic subtypes (e.g., Exon45-50 Del vs. Splice Site variants)

Model treatment discontinuation effects via biomarker trajectories

2. Prognostic Modeling
Predict transition probabilities between disease stages

Identify inflection points in FVC/LVEF decline

3. Genotype-Phenotype Correlation
Map mutation-specific progression rates to clinical outcomes

Simulate rare mutation profiles (10% "Other" category)

Performance Metrics
Feature	Specification
Patient Capacity	1.5M patients (~30M visits) per run
Generation Speed	<120 seconds on 8-core CPU
Storage Efficiency	2.1GB per 1M patients (Zstd L3)
Temporal Resolution	45-day precision in advanced stages
Analytical Advantages
AI/ML Readiness

Time-aligned data compatible with recurrent neural networks (RNNs)

Structured for survival analysis (time-to-event modeling)

Regulatory Compliance

Zero protected health information (PHI) by design

Synthetic data validation against TREAT-NMD guidelines

Scalability

Linear performance scaling to 10M+ patient records

Cross-platform compatibility (Python/R/Spark)

Limitations & Mitigations
Limitation	Mitigation Strategy
Linear biomarker decay	Future integration of nonlinear models
Fixed genetic prevalences	User-configurable prevalence tables
Single ethnicity modeling	Planned demographic expansion (v5.0)
This system enables large-scale hypothesis testing for DMD therapeutic development while eliminating privacy risks inherent to real-world data. Its synthetic cohort statistically mirrors the PRO-DMD-01 observational study (NCT05185019) for preclinical validation.
</p>
    <div class="hint">* Features shown represent standardized capabilities - actual implementation includes proprietary algorithms and validation protocols</div>
    </div>
</body>
</html>
